https://ancavasculitisnews.com/news/keeping-egpa-remission-fasenra-treatment-does-no-worse-than-nucala/
For keeping EGPA in remission, Fasenra treatment does no worse that Nucala | ANCA Vasculitis News
Developer AstraZeneca intends to request that Fasenra be approved as a treatment for eosinophilic granulomatosis with polyangiitis (EGPA).
https://www.terveyskirjasto.fi/far04566/fasenra
FASENRA - Terveyskirjasto
fasenraterveyskirjasto